Forward P/S Multiple: iCAD Corp (ICAD)

Corporate emblem and logo of iCAD Inc. (ICAD)

The forward P/S chart for iCAD, Inc. (ICAD) demonstrates the resilience of an asset shielded from macroeconomic volatility by stable demand for medtech. Growth is driven by the expansion of B2B subscriptions for AI software in radiology centers and partnerships with equipment behemoths. The mass adoption of early breast cancer detection systems is stimulating revenue. The value of 5.50 determines the current status of the sales valuation parameter.

iCAD Corp - ICAD Market Cap to Projected Revenue (period 07/04/2022 - 08/02/2025)

Analytical breakdowns for iCAD, Inc.

- current price and projected stock value:
Stock Price iCAD|ICAD - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization iCAD, Inc.|ICAD - Enterprise Value
- issuer book value statistics:
Book Value per Share iCAD|ICAD - Accounting Capitalization|Market Cap to Net Assets Ratio icadmed.com|ICAD - Aggregate Asset Value
- issuer credit burden and liquidity indicators:
Total Debt to Capital iCAD, Inc.|ICAD - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity iCAD|ICAD - Company Aggregate Debt|Debts to Book Capitalization iCAD, Inc.|ICAD - Company Long-Term Liabilities|Company Current Liabilities iCAD|Quick Ratio icadmed.com
- financial results and valuation multiples details:
ICAD - Net Financial Result|Projected Future Earnings iCAD, Inc.|ICAD - Price to Earnings Ratio|Forward P/E Multiple iCAD|ICAD - PEG Multiple|EV/EBITDA Multiple iCAD, Inc.|ICAD - Operating profit before amortization|Net earnings per share (EPS TTM) iCAD|ICAD - Net earnings per share for the last 12 months|Quarterly EPS earnings growth icadmed.com|ICAD - Earnings growth in current year|Net earnings per share growth forecast for next year iCAD, Inc.
- sales and revenue indicators:
ICAD - Company Sales Volume|Projected Sales Volume iCAD|ICAD - Market Cap to Revenue|Forward P/S Multiple iCAD, Inc.
Fundamental company valuation:iCAD Corp ICAD
Product sample of iCAD

Patents and FDA approval for AI-driven breast cancer diagnostics create high barriers to entry for competitors, which is reflected in the forward P/S ratio of 5.50 for iCAD, Inc. (ICAD). This indicator is calculated as the ratio of market capitalization to projected revenue, allowing investors to assess the extent to which future sales expectations are priced in and determine the asset's degree of overboughtness.

Competitors of iCAD, Inc. (ICAD)

Forward P/S Multiple ONC (BeiGene)|HALO - Forward Price-to-Revenue Multiple|RevMed - Forward P/S Multiple|AAPG - Forward P/S Multiple|CGON: Forward P/S Multiple|Market Cap to Projected Revenue URGN|Forward Price-to-Revenue Multiple BCAX|PSNL: Forward Price to Sales|Forward P/S Multiple ERAS|Market Cap to Expected Sales Ratio Delcath Corp|Price-to-Projected Revenue Ratio Y-mAbs Therapeutics YMAB|AURA: Market Cap to Projected Revenue|Candel - Forward P/S Multiple|Accuray Inc (ARAY) - Forward Price-to-Revenue Multiple|SLS (sellaslifesciences.com) - Forward Price-to-Revenue Multiple|ACTU - Market Cap to Expected Sales Ratio|CTOR (Citius Oncology, Inc.) - Forward P/S Multiple|TuHURA (HURA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TARA|Forward Price-to-Revenue Multiple Fate Therapeutics Inc FATE|Forward P/S Multiple WHWK (Aadi Bioscience)|Forward P/S Multiple TScan Therapeutics Inc TCRX|Champions Oncology Corp - Forward P/S Multiple|XBIT (XBiotech Inc.) - Market Cap to Projected Revenue|CVM: Forward P/S Multiple|Forward Price-to-Revenue Multiple OS Therapies Inc.|RADX (Radiopharm Theranostics Limited) - Forward P/S Multiple|Forward P/S Multiple Artiva|Price-to-Projected Revenue Ratio Adlai Nortye Ltd. (ANL)|verupharma.com - Market Cap to Projected Revenue|Forward P/S Multiple TPST (Tempest Therapeutics, Inc.)|XLO - Forward Price-to-Revenue Multiple|Enochian BioSciences - Forward P/S Multiple|Market Cap to Future Revenue Ratio Mural Oncology plc|kairospharma.com (KAPA) - Price-to-Projected Revenue Ratio|OnKure Therapeutics - Forward Price to Sales|Forward Price-to-Revenue Multiple GDTC|CRIS: Forward Price to Sales|Forward P/S Multiple APLM|Forward Price-to-Revenue Multiple Tharimmune Corporation THAR|Advanced Biomed - Forward Price-to-Revenue Multiple|Forward P/S Multiple genprex.com GNPX|CLDI - Price-to-Projected Revenue Ratio|Forward Price to Sales SBFM (Sunshine Biopharma Inc.)|XBIO: Forward P/S Multiple|Market Cap to Future Revenue Ratio Salarius Pharma (SLRX)|PPBT (Purple Biotech) - Forward P/S Multiple|AON (AONC) - Market Cap to Expected Sales Ratio|Forward P/S Multiple BGNE|Forward Price-to-Revenue Multiple Checkpoint Therapeutics Inc. CKPT|Forward P/S Multiple ELEV (Elevation Oncology, Inc.)|Forward P/S Multiple Ikena Oncology Inc. IKNA|Notable Labs, Ltd. - Forward P/S Multiple|VIRX (Viracta Therapeutics) - Market Cap to Projected Revenue|MOR (MorphoSys) - Forward Price-to-Revenue Multiple|NAYA Biosciences Inc - Forward Price to Sales|AAPGV (Ascentage Pharma Group Ltd) - Forward P/S Multiple